Comprehensive Pharmacology of Antiviral Drugs Compiled May 01 2025 Introduction Antiviral pharmacology has advanced from the single-agent era of idoxuridine to a modern arsenal including polymerase terminators, protease blockers, monoclonal antibodies, and host-directed entry inhibitors. Because viruses are obligate intracellular parasites, therapy emphasises selective toxicity—halting viral replication without irreparable host harm. This page delivers a section-wise, visually enhanced overview of the major antiviral classes, mechanisms, PK profiles, indications, resistance, and safety. 1. General Principles of Antiviral Therapy Virustatic: Most agents inhibit assembly/release rather than destroy virions. Stage specificity: Entry, uncoating, genome replication, integrase, or release. Early use: Greatest efficacy when given before peak viral load (e.g., oseltamivir ≤ 48 h). Combination therapy: Mandatory for HIV/HCV to curb resistance. Host factors: Renal/hepatic status, pregnancy, pharmacogenomics (CYP3A4, HLA-B*57:01) drive selection. 2. Anti-Herpesvirus Agents 2.1 Nucleoside Analogues DrugActivationMechanismPK HighlightsMajor Toxicities AcyclovirHSV TK ➜ host kinasesDNA-pol chain terminationIV/PO; CSF ≈50 %Crystalline nephropathy, neurotoxicity at high dose ValacyclovirPro-acyclovir (↑ F 55 %)SamePO onlySimilar, less frequent GanciclovirUL97 kinaseDNA-pol inhibition + terminationIV; low PO FMyelosuppression, CNS effects ValganciclovirPro-ganciclovirSamePO F 60 %As above CidofovirHost kinases onlyDNA-pol inhibitorIV; long IC t½Renal toxicity (⇣ with probenecid + saline) FoscarnetNone (pyrophosphate)Blocks DNA-pol/RTIV; CSF 70 %Nephrotoxicity, ↓ Ca²⁺/Mg²⁺, seizures Resistance TK-negative HSV mutants resist acyclovir; CMV UL97/DNA-pol mutants limit ganciclovir and cidofovir; foscarnet holds until polymerase mutations arise. 3. Anti-Influenza Drugs 3.1 M2 Ion-Channel Inhibitors Amantadine & rimantadine block influenza A uncoating—now obsolete due to universal resistance. 3.2 Neuraminidase Inhibitors DrugSpectrumRouteClinical Notes OseltamivirA & BPON/V; rare neuropsychiatric events ZanamivirA & BInhaledBronchospasm—avoid asthma/COPD PeramivirA & BIV (single dose)Diarrhoea 3.3 Cap-Endonuclease Inhibitor Baloxavir marboxil (single-dose PO) halts PA-mediated “cap-snatching”. I38T mutations reduce susceptibility. 4. Anti-RSV & Emerging Respiratory Viruses Ribavirin: Guanosine analogue (inhaled/PO/IV); haemolytic anaemia, teratogenic. Palivizumab / Nirsevimab: mAbs vs RSV F-protein for prophylaxis. Remdesivir: IV RdRp inhibitor (SARS-CoV-2); monitor LFTs. Molnupiravir: PO pro-mutagen; avoid pregnancy. Nirmatrelvir ± ritonavir: Oral 3CLpro inhibitor (Paxlovid); major CYP3A4 DDIs. 5. Anti-Hepatitis Agents 5.1 HBV Peg-IFN-α: Weekly SC; flu-like, depression. NRTI-like agents: Entecavir, TDF/TAF (high barrier) vs lamivudine (low-barrier M204V). 5.2 HCV – Direct-Acting Antivirals ClassSuffixPrototypeKey Point NS3/4A PI-previrGlecaprevirCI in Child-Pugh B/C NS5A Inhibitor-asvirVelpatasvirWell-tolerated NS5B Nuc Pol Inhib.-buvirSofosbuvirBradycardia w/ amiodarone 5.3 HDV Bulevertide (SC) blocks NTCP entry; first licensed HDV drug. 6. Antiretroviral Therapy (HIV-1/2) Standard regimen: 2 NRTIs + 1 high-barrier anchor (INSTI > boosted PI > NNRTI). 6.1 NRTIs Tenofovir (TDF/TAF): renal/BMD issues (less with TAF). Emtricitabine / Lamivudine: cytidine analogues (M184V). Abacavir: HLA-B*57:01 hypersensitivity. Zidovudine: anaemia; IV intrapartum prophylaxis. 6.2 NNRTIs & 6.3 Protease Inhibitors Efavirenz (CNS dreams); rilpivirine (needs acid). Darunavir (rash, high barrier); atazanavir (hyperbilirubinaemia), all boosted by ritonavir/cobicistat (CYP3A4 DDIs). 6.4 INSTIs & 6.5 Entry/Fusion Dolutegravir & bictegravir are first-line; long-acting IM cabotegravir/rilpivirine monthly. Maraviroc (CCR5), enfuvirtide (gp41), ibalizumab (post-attachment). 7. Anti-Poxvirus Drugs Tecovirimat: VP37 inhibitor (smallpox/monkeypox). Brincidofovir / Cidofovir: DNA-pol inhibitors for severe cases. 8. Pharmacokinetic Considerations Renal clearance: acyclovir, ganciclovir, TDF ➜ dose adjust CKD. Hepatic CYP3A4: PIs, NNRTIs, baloxavir ➜ beware DDIs. Prodrugs: valacyclovir, oseltamivir, baloxavir, TAF. Depot injections: cabotegravir/rilpivirine improve adherence but linger if ADRs occur. 9. Resistance Mechanisms HIV RT: M184V (lamivudine/emtricitabine) • K65R (tenofovir). HIV Protease: D30N, I50L. Influenza NA: H275Y (oseltamivir-R). HSV: TK-negative mutants. 10. Adverse-Effect Themes & Monitoring Bone marrow: ganciclovir, zidovudine ➜ CBC. Kidney: cidofovir, foscarnet, TDF ➜ Cr, phosphate. Neuropsychiatric: efavirenz dreams, IFN depression. Metabolic: lipodystrophy with older PIs. Mitochondrial: stavudine, didanosine. 11. Special Populations Pregnancy: Dolutegravir backbone; avoid ribavirin, molnupiravir. Neonates: IV acyclovir, oseltamivir, palivizumab prophylaxis. Transplant: Valganciclovir prophylaxis for CMV. Elderly: Polypharmacy ➜ PI/Paxlovid DDIs. 12. Immunomodulatory & Passive Agents Interferon-α: activates JAK-STAT antiviral genes; flu-like, depression. mAbs: RSV (palivizumab), SARS-CoV-2 (variant-dependent), HIV (ibalizumab). Vaccines reduce antiviral demand (influenza, HBV, SARS-CoV-2). 13. Emerging & Future Therapies Broad-spectrum RdRp inhibitors (favipiravir, bemnifosbuvir). Host-targeted cyclophilin inhibitors for HCV. CRISPR-Cas9 excision of HIV provirus (pre-clinical). Long-acting implants (islatravir, cabotegravir) for HIV PrEP. Universal coronavirus fusion blockers & nasal peptides. 14. Conclusion The antiviral pharmacopeia epitomises the synergy of molecular virology and medicinal chemistry, converting lethal infections into manageable or curable diseases. Ongoing innovation remains essential to outpace resistance, PK variability, and emerging pathogens. Selected Textbook References Goodman & Gilman’s Pharmacological Basis of Therapeutics (14th ed., 2023). Basic & Clinical Pharmacology (15th ed., 2021). Rang & Dale’s Pharmacology (10th ed., 2022). Mandell, Douglas, Bennett’s Infectious Diseases (9th ed., 2020). De Clercq E., Li G. Approved Antiviral Drugs (2021). Antiviral Chemotherapy & Chemoprophylaxis (4th ed., 2019). Hill A. Global Antiviral Pharmacology (2022). © 2025 — Educational use only.
